Compounds > enzastaurin
Page last updated: 2024-09-05

enzastaurin and su 11248

enzastaurin has been researched along with su 11248 in 6 studies

Compound Research Comparison

Studies
(enzastaurin)		Trials
(enzastaurin)		Recent Studies (post-2010)
(enzastaurin)		Studies
(su 11248)		Trials
(su 11248)		Recent Studies (post-2010) (su 11248)
18852994,3385603,200

Protein Interaction Comparison

ProteinTaxonomyenzastaurin (IC50)su 11248 (IC50)
Serine/threonine-protein kinase Chk1Homo sapiens (human)0.0773
Aurora kinase AHomo sapiens (human)1.837
Solute carrier family 22 member 1 Homo sapiens (human)6.1
NUAK family SNF1-like kinase 1Homo sapiens (human)0.048
Serine/threonine-protein kinase PAK 4Homo sapiens (human)0.5692
Serine/threonine-protein kinase Chk2Homo sapiens (human)0.0168
Tyrosine-protein kinase ABL1Homo sapiens (human)0.8423
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.555
Epidermal growth factor receptorHomo sapiens (human)0.48
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.0186
Insulin receptorHomo sapiens (human)3.2
Tyrosine-protein kinase LckHomo sapiens (human)0.0089
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0888
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.35
Hepatocyte growth factor receptorHomo sapiens (human)4.0002
Tyrosine-protein kinase HCKHomo sapiens (human)0.19
Platelet-derived growth factor receptor betaHomo sapiens (human)0.211
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.2639
Fibroblast growth factor receptor 1Homo sapiens (human)1.4228
AromataseHomo sapiens (human)0.018
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.2764
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.061
Translocator proteinRattus norvegicus (Norway rat)0.039
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0457
AcetylcholinesteraseHomo sapiens (human)5.87
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)0.0186
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.009
G protein-coupled receptor kinase 5Homo sapiens (human)0.83
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0089
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1116
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0581
Casein kinase I isoform alphaHomo sapiens (human)0.001
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)0.1839
5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)0.0617
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.018
Angiopoietin-1 receptorHomo sapiens (human)0.018
Focal adhesion kinase 1Homo sapiens (human)1.6
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)3.8389
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)0.158
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)0.1313
AP2-associated protein kinase 1Homo sapiens (human)0.0462
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)0.0215
Aurora kinase BHomo sapiens (human)1.5
Serine/threonine-protein kinase TBK1Homo sapiens (human)0.22
ALK tyrosine kinase receptorHomo sapiens (human)1.1773
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Berger, W; Lamm, W; Micksche, M; Pichelmeyer, O; Pirker, C; Schmidinger, M; Vogl, UM; Zielinski, CC1
Decker, R; Escudier, B; Faelker, T; Hamid, O; Kania, M; Kelly, CS; Schmidinger, M; Sternberg, CN; Szczylik, C1
Anderson, KC; Podar, K1

Reviews

1 review(s) available for enzastaurin and su 11248

ArticleYear
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011

Trials

1 trial(s) available for enzastaurin and su 11248

ArticleYear
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; International Agencies; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Tissue Distribution; Treatment Outcome

2012

Other Studies

4 other study(ies) available for enzastaurin and su 11248

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
    Cancer letters, 2009, May-18, Volume: 277, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase C; Protein Kinase C beta; Pyridines; Pyrroles; Ribosomal Protein S6 Kinases; Signal Transduction; Sorafenib; Sunitinib

2009